Literature DB >> 11448286

Durable HIV treatment benefit despite low-level viremia: reassessing definitions of success or failure.

S G Deeks.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11448286     DOI： 10.1001/jama.286.2.224

Source DB:  PubMed          Journal:  JAMA        ISSN： 0098-7484            Impact factor:   56.272


× No keyword cloud information.
  11 in total

1.  Structured treatment interruptions with tenofovir monotherapy for simian immunodeficiency virus-infected newborn macaques.

Authors:  Koen K A Van Rompay; Raman P Singh; Walid Heneine; Jeffrey A Johnson; David C Montefiori; Norbert Bischofberger; Marta L Marthas
Journal:  J Virol       Date:  2006-07       Impact factor: 5.103

2.  HIV Drug Resistance Profiles and Clinical Outcomes in Patients with Viremia Maintained at Very Low Levels.

Authors:  Michael R Jordan; Julie Winsett; Aileen Tiro; Vuth Bau; Rony S Berbara; Christopher Rowley; Nobel Bellosillo; Christine Wanke; Eoin P Coakley
Journal:  World J AIDS       Date:  2013-06

3.  Human immunodeficiency virus type 1 env evolves toward ancestral states upon transmission to a new host.

Authors:  Joshua T Herbeck; David C Nickle; Gerald H Learn; Geoffrey S Gottlieb; Marcel E Curlin; Laura Heath; James I Mullins
Journal:  J Virol       Date:  2006-02       Impact factor: 5.103

4.  HIV drug resistance detected during low-level viraemia is associated with subsequent virologic failure.

Authors:  Luke C Swenson; Jeong Eun Min; Conan K Woods; Eric Cai; Jonathan Z Li; Julio S G Montaner; P Richard Harrigan; Alejandro Gonzalez-Serna
Journal:  AIDS       Date:  2014-05-15       Impact factor: 4.177

5.  Multiple viral genetic analyses detect low-level human immunodeficiency virus type 1 replication during effective highly active antiretroviral therapy.

Authors:  Lisa M Frenkel; Yang Wang; Gerald H Learn; Jennifer L McKernan; Giovanina M Ellis; Kathleen M Mohan; Sarah E Holte; Shannon M De Vange; Diane M Pawluk; Ann J Melvin; Paul F Lewis; Laura M Heath; Ingrid A Beck; Madhumita Mahalanabis; Wilscott E Naugler; Nicole H Tobin; James I Mullins
Journal:  J Virol       Date:  2003-05       Impact factor: 5.103

6.  Diminished replicative fitness of primary human immunodeficiency virus type 1 isolates harboring the K65R mutation.

Authors:  Jan Weber; Bikram Chakraborty; Jitka Weberova; Michael D Miller; Miguel E Quiñones-Mateu
Journal:  J Clin Microbiol       Date:  2005-03       Impact factor: 5.948

7.  Effect of suppressing HIV viremia on the HIV progression of patients undergoing a genotype resistance test after treatment failure.

Authors:  M Zaccarelli; P Lorenzini; V Tozzi; F Forbici; F Ceccherini-Silberstein; C Gori; R D'Arrigo; M P Trotta; P Narciso; C F Perno; A Antinori
Journal:  Infection       Date:  2009-03-09       Impact factor: 3.553

8.  CCL3L1-CCR5 genotype influences durability of immune recovery during antiretroviral therapy of HIV-1-infected individuals.

Authors:  Sunil K Ahuja; Hemant Kulkarni; Gabriel Catano; Brian K Agan; Jose F Camargo; Weijing He; Robert J O'Connell; Vincent C Marconi; Judith Delmar; Joseph Eron; Robert A Clark; Simon Frost; Jeffrey Martin; Seema S Ahuja; Steven G Deeks; Susan Little; Douglas Richman; Frederick M Hecht; Matthew J Dolan
Journal:  Nat Med       Date:  2008-03-30       Impact factor: 53.440

9.  Novel single-cell-level phenotypic assay for residual drug susceptibility and reduced replication capacity of drug-resistant human immunodeficiency virus type 1.

Authors:  Haili Zhang; Yan Zhou; Cecily Alcock; Tara Kiefer; Daphne Monie; Janet Siliciano; Quan Li; Paul Pham; Joseph Cofrancesco; Deborah Persaud; Robert F Siliciano
Journal:  J Virol       Date:  2004-02       Impact factor: 5.103

10.  Escape of HIV-1 from a small molecule CCR5 inhibitor is not associated with a fitness loss.

Authors:  Cleo G Anastassopoulou; Andre J Marozsan; Alexandre Matet; Amy D Snyder; Eric J Arts; Shawn E Kuhmann; John P Moore
Journal:  PLoS Pathog       Date:  2007-06       Impact factor: 6.823
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.